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Activation of the proteolytic plasminogen activator sys-
tem plays a central role for extracellular matrix degrada-
tion under various physiological and pathological condi-
tions including blood clotting or cancer invasion (Schmitt
et al., 1997; Andreasen et al., 2000; Sperl et al., 2001). In
the skin, epidermal keratinocytes synthesize and secrete
the urokinase-type plasminogen activator (uPA), which
binds to its specific receptor (uPAR) on the keratinocyte
surface. There, uPA proteolytically activates cell surface-
bound plasminogen, which in turn cleaves many extra-
cellular matrix components providing pericellular proteol-
ysis (Kramer et al., 1995). UPA activity is controlled by the
specific plasminogen activator inhibitors, PAI-1 and PAI-
2. Besides its importance for the reepithelialization of cu-
taneous wounds (Romer et al., 1996; Braungart et al.,
2001), the plasminogen activator system has also been
implicated in the pathophysiology of pemphigus, an au-
toimmune blistering disease of the skin and mucous
membranes. Pemphigus is caused by autoantibodies
that recognize the desmosomal proteins desmoglein 3
(pemphigus vulgaris) or desmoglein 1 (pemphigus foli-
aceus). Desmosomes are the principal adhesion struc-
tures between epidermal keratinocytes. Binding of
desmoglein autoantibodies leads to the destruction of
desmosomes, resulting in the loss of cell-cell adhesion
(acantholysis), and the formation of epidermal blisters
(Amagai 1996; Koch et al., 1997). While there is solid ex-
perimental evidence for autoantibodies being the primor-
dial cause of the disease, this cannot answer all ques-
tions, e.g., why blisters develop only at certain skin areas,
although autoantibodies are present within the entire
skin. One attempt to account for this observation con-
cerns the plasminogen activator system, whose upregu-
lation has been considered as one mechanism that may –
subsequent to the binding of autoantibodies to desmo-
somes – contribute to acantholysis and blister formation.
This view is supported by several observations: (i) in-
creases of uPA (Schaefer et al., 1996) or tPA (Jensen
et al., 1988; Baird et al., 1990) were detected in lesional,
but not uninvolved, epidermis of pemphigus patients; (ii)
in cultured keratinocytes, IgG serum fractions from pa-
tients with pemphigus vulgaris induce expression of uPA
(Wilkinson et al., 1989) and uPAR (Seishima et al., 1997);
(iii) pemphigus-IgG or plasminogen-induced acantholy-
sis in skin organ cultures was inhibited by anti-uPA anti-
bodies (Morioka et al., 1987), anti-uPAR antibodies (Xue
et al., 1998), or purified PAI-2 (Hashimoto et al., 1989).
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Pemphigus is an autoimmune blistering disease of
the skin and mucous membranes. It is caused by au-
toantibodies directed against desmosomes, which
are the principal adhesion structures between epi-
dermal keratinocytes. Binding of autoantibodies
leads to the destruction of desmosomes resulting in
the loss of cell-cell adhesion (acantholysis) and epi-
dermal blisters. The plasminogen activator system
has been implicated as a proteolytic effector in pem-
phigus. We have tested inhibitors of the plasminogen
activator system with regard to their potential to pre-
vent pemphigus-induced cutaneous pathology. In a
human split skin culture system, IgG preparations of
sera from pemphigus vulgaris patients caused
histopathologic changes (acantholysis) similar to
those observed in the original pemphigus disease. All
inhibitors that were tested (active site inhibitors di-
rected against uPA, tPA, and/or plasmin; antibodies
neutralizing the enzymatic activity of uPA or tPA; sub-
stances interfering with the binding of uPA to its spe-
cific cell surface receptor uPAR) failed to prevent
pemphigus vulgaris IgG-mediated acantholysis. Plas-
minogen-mediated acantholysis, however, was effec-
tively antagonized by the synthetic active site serine
protease inhibitor WX-UK1 or by p-aminomethylben-
zoic acid. Our data argue against applying anti-plas-
minogen activator/anti-plasmin strategies in the
management of pemphigus.
Key words: Acantholysis /Pemphigus /Plasminogen
activator system/Protease inhibitors /Skin organ culture.
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However, the relevance of the plasminogen activator sys-
tem is questioned by the observation that in neonatal
mice, despite a deficiency for plasminogen activators,
pemphigus IgG induced epidermal blisters (Mahoney
et al., 1999).
Pemphigus is currently primarily treated with systemic
glucocorticoids and other immunosuppressants. There-
fore, the inhibition of plasminogen-mediated proteolysis
could become a suitable complementary pharmacologic
concept allowing to reduce side-effect prone immuno-
suppressive therapies.
In this study, we have explored the potential of various
inhibitors of the plasminogen system, including specific
active site inhibitors of plasminogen activators, to inter-
fere with pemphigus-induced acantholysis in a human
skin organ culture system. In this model, human skin ex-
plants are exposed to IgG preparations of sera from pem-
phigus patients. The resulting pathologic changes re-
semble those observed in the original pemphigus
disease (Michel and Ko 1974; Barnett et al., 1977). 
Exposure of human split skin samples to pemphigus-
vulgaris IgG for 24 h resulted in the appearance of
epidermal clefts and acantholytic cells in the suprabasal
epidermal layers (Figure 1A). There was also the charac-
teristic ‘tombstone’ layer of basal keratinocytes adjacent
to the dermo-epidermal junction, which is due to ker-
atinocytes that remain attached to the basal membrane
via hemidesmosomes. Hemidesmosomes, as opposed
to desmosomes, are not recognized and damaged by
pemphigus autoantibodies. As a control, incubation of
skin explants with an IgG fraction of serum from a healthy
donor did not affect the integrity of the skin explant (Fig-
ure 1B). This excludes the presence of relevant amounts
of plasminogen/plasmin or other proteolytically active
substances in the IgG preparations and suggests that the
observed acantholysis was an autoantibody-specific ef-
fect.
In order to delineate the contribution of the plasmino-
gen activator system to pemphigus-associated acanthol-
ysis and to explore the preventive potential of interference
with the plasminogen activator system, a panel of broad
or specific inhibitors of the plasminogen activator system
(Table 1) was added to the explant culture medium prior to
exposure to pemphigus vulgaris IgG, and their effects on
acantholysis was monitored histologically. The inhibitors
were added to the skin explant culture medium at toxico-
logically tolerable and therapeutically feasible concentra-
tions 150 min prior to pemphigus vulgaris IgG (24 h incu-
bation). The synthetic active site inhibitors (for details see
Table 1) WX-UK1 (10 – 20 µM) and WX-293 (50 – 100 µM),
or p-aminomethylbenzoic acid (1 µg/ml, 6.62 µM) did not
affect pemphigus vulgaris IgG-mediated acantholysis.
Furthermore, the application of an anti-uPA mAb (inhibit-
ing enzymatic activity of uPA, 100 µg/ml), an anti-uPAR
mAb (blocking uPA/uPAR-interaction; 100 µg/ml), or a
cyclic peptide interfering with uPA/uPAR-interaction
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Fig. 1 Pemphigus IgG Causes Epidermal Acantholysis in Human Split Skin Explants.
Explants of normal human skin were generated from 0.4 mm thick split skin produced and left over during skin transplantation proce-
dures. Informed consent had been obtained from all patients prior to surgical removal. Explants were trimmed to 4×4 mm pieces and
placed epidermis side up in Dulbecco’s modified Eagle medium supplemented with 15 mM HEPES (Sigma, Deisenhofen, Germany),
2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 1 µg/ml amphotericin B (all from Life Technologies, Karlsruhe, Germany)
in the absence of serum. Incubation was carried out (A) with pemphigus vulgaris IgG (237 µg/ml) or (B) with IgG (237 µg/ml) from a
healthy control donor for 24 h at 37°C and 5% CO2. Explants were then harvested and processed for histologic examination (formalin
fixation, paraffin embedement, and hematoxylin-eosin staining). Histologic specimens were viewed at an Axioskop 2 microscope (Carl
Zeiss, Jena, Germany) and photographed. (A) and (B) are hematoxylin- and eosin-stains. IgG fractions were prepared using CaCl2/dex-
trane sulfate precipitation, and sequential column affinity chromatography with lysine-Sepharose and protein A Sepharose columns.
Chromatography fractions containing IgG were pooled, dialyzed against phosphate-buffered saline, and sterile filtered. IgG was from
patients with pemphigus vulgaris, none of which had received specific immunosuppressive therapy prior to serum collection. In the ex-
periment displayed IgG from a pemphigus vulgaris patient experiencing a disease flare-up was used. By indirect immunofluorescence,
his serum pemphigus antibody titer was 160 (monkey esophagus as substrate). As a control, serum was also collected from normal
donors, and IgG was prepared in an identical manner along with pemphigus vulgaris sera. One representative of three independent ex-
periments is shown. Similar results were obtained with IgG-preparations from two additional donors (data not shown). 
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(WX-374; 10 – 100 µM) did also not prevent pemphigus
vulgaris-IgG-mediated acantholysis, nor did preincuba-
tion with a tPA-neutralizing antiserum (100 µg/ml) or the
tPA-selective synthetic active site inhibitor, tPAstop
(1.5 – 15 µM). All inhibitory substances were tested in at
least three independent experiments. In the concentra-
tions used, these substances did not produce any dis-
cernible toxicity in skin explants when applied separately
(data not shown). Similar results were obtained with IgG
preparations from three different donors with pemphigus
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Table 1 Inhibitors of Plasminogen Activation.
WX-UK1 3-Amidinophenylalanine-based serine protease inhibitor (Stürzebecher et al., 1999);
Ki [uPA]: 0.41 µM; Ki [tPA]: 4.9 µM; Ki [plasmin]: 0.39 µM
WX-UK1-D Inactive D-enantiomer of WX-UK1
WX-293 Phenylguanidine-based inhibitor specific for uPA (Sperl et al., 2000);
Ki [uPA]: 2.12 µM; Ki [tPA]: > 1000 µM; Ki [plasmin]: > 1000 µM
p-Aminomethylbenzoic Synthetic lysine analog (Sigma, Steinheim, Germany); suppresses plasminogen conversion to plasmin 
acid (Dobrev et al., 1996)
tPAstop Synthetic selective tPA inhibitor (American Diagnostica, Pfungstadt, Germany);
Ki [tPA]: 0.082 µM; Ki[uPA]: 3.4 µM; Ki[plasmin]: 6.4 µM
WX-374 Cyclic peptide cyclo21,29[D-Cys21Orn23Cys29]-uPA21 – 30; inhibits uPA/uPAR-interaction with an IC50 of 280 nM
(derived from cyclo21,29[D-Cys21Cys29]-uPA21 – 30 (Guthaus et al., 2002)
Anti-uPAR Mouse IgG1 monoclonal (mAb) IIIF10 directed to human uPAR; blocks uPA/uPAR-interaction (Luther et al.,
1997)
Anti-uPA Mouse IgG1 mAb directed against human uPA; neutralizes enzymatic activity of uPA (American Diagnostica)
Anti-tPA Goat polyclonal antibodies directed to human tPA; neutralizes enzymatic activity of tPA (American
Diagnostica)
Fig. 2 Plasminogen-Mediated Acantholysis Is Inhibited by Synthetic Serine Protease Inhibitors.
Skin explants were prepared and maintained as described in the legend to Figure 1. Results of 24 h exposure to human plasminogen
alone (0.26 mg/ml, Roche Diagnostics, Mannheim, Germany) (A) or, additionally, to 1 µg/ml (6.62 µM) p-aminomethylbenzoic acid (B),
50 µM WX-UK1 (C), or 50 µM WX-UK1-D (D). The additional substances in (B)-(D) were added 150 min prior to plasminogen and were
present for the whole 24 h of plasminogen exposure. Samples were hematoxylin- and eosin-stained. One representative of three inde-
pendent experiments is shown.
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vulgaris. Thus, various inhibitors of the plasminogen acti-
vator system failed to prevent pemphigus vulgaris IgG-in-
duced acantholysis.
In order to rule out that this failure was due to limita-
tions of the experimental setting, we assessed the poten-
tial of inhibitors to interfere with plasminogen-mediated
acantholysis. Plasminogen is present in normal epider-
mis (Isseroff and Rifkin, 1983), but skin explants display a
normal epidermal architecture (Figure 1B) even after pro-
longed incubation periods (Dobrev et al., 1996), suggest-
ing that plasminogen is not sufficiently activated or plas-
minogen/plasmin is not present in sufficient amounts to
cause acantholysis. However, if plasminogen is added in
non-physiologically high concentrations, it enhances
pemphigus IgG-induced epidermal acantholysis (Hashi-
moto et al., 1983) or can, by itself, produce acantholysis
in skin organ culture (Morioka et al., 1987). In our experi-
ments, the incubation of skin explants with plasminogen
indeed produced marked acantholysis (Figure 2A), and
this acantholysis was completely prevented by the
presence of two different inhibitory agents, either
p-aminomethylbenzoic acid (1 µg/ml, 6.62 µM, Figure 2B)
as previously described (Dobrev et al., 1996) or WX-UK1
(10 – 50 µM, Figure 2C). However, if WX-UK1-D, the bio-
logically inactive D-enantiomer of WX-UK1, was applied
along with plasminogen, there was still marked acanthol-
ysis (Figure 2D). These experiments demonstrate func-
tional inhibition of the plasminogen activator system by
the substances applied.
In our study various inhibitors of the plasminogen acti-
vator system failed to prevent pemphigus vulgaris-IgG-
mediated acantholysis and epidermal blistering in skin
explants, whereas they effectively blocked plasminogen-
mediated acantholysis. We could not confirm previous
reports about the prevention of pemphigus-induced
acantholysis by interference with the plasminogen acti-
vator system in explant skin models using anti-uPA anti-
bodies (Morioka et al., 1987), anti-uPAR antibodies (Xue
et al., 1998), PAI-2 (Hashimoto et al., 1989) or low-molec-
ular weight inhibitors (Naito et al., 1989; Dobrev et al.,
1996). The reason for this discrepancy is not clear, but
may be related to differences in the experimental setting.
It seems possible that a minor effector role of the plas-
minogen activator system can be uncovered in a situa-
tion in which the acantholytic capacity of the autoanti-
bodies is suboptimal. In previous studies, e.g. due to
using full skin thickness preparations (Morioka et al.,
1987; Hashimoto et al., 1989; Xue et al., 1998), the epi-
dermis may have been less accessible to autoantibodies
than in our situation with split skin explants. Furthermore,
compared to highly purified IgG preparations used in this
study, unfractioned serum (Dobrev et al., 1996) may have
contained much less autoantibodies and caused less
complete disruptive damage to desmosomes. Similar
considerations may apply for IgG preparations from
serum with lower autoantibody titers or for sera with au-
toantibodies of lower affinity. In addition, it cannot be ex-
cluded that if the plasminogen activator system is strong-
ly activated locally, higher, and possibly toxic, doses of
inhibitory substances may be required to completely in-
hibit plasminogen activation.
Our extensive testing of an array of inhibitors of the
plasminogen activator system (Table 1) argues against
the plasminogen activator system playing a major role in
producing acantholysis. This view is also supported, and
therapeutic approaches are further discouraged, by
studies using animal models for pemphigus: (i) synthetic
serine protease inhibitors failed to prevent pemphigus
vulgaris IgG-induced blister formation in a neonatal
mouse model (Naito et al., 1989); (ii) whereas dexametha-
son markedly suppressed pemphigus IgG-induced plas-
minogen activator activity, it did not prevent pemphigus
IgG-induced blistering (Anhalt et al., 1986); (iii) desmo-
glein 3-deficient mice display a phenotype similar to
pemphigus vulgaris patients (Koch et al., 1997), suggest-
ing that loss of function of this desmosomal protein, ei-
ther by pemphigus autoantibodies or via genetic knock
out, is sufficient for acantholysis and blister formation;
and (iv) most importantly, in neonatal mice deficient for
either uPA or tPA, or deficient for both uPA and tPA, pem-
phigus IgG-induced epidermal blisters were observed to
the same degree as in normal controls (Mahoney et al.,
1999).
In conclusion, the data demonstrate that plasminogen
activation/plasmin inhibition does not prevent pemphi-
gus acantholysis and do not support the application of
anti-plasminogen activator/plasmin strategies in the
management of pemphigus.
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